CEA and Proteus, Immuno’line™ for evaluating the immunogenicity of therapeutic proteins

Nimes, France, Sept 26, 2007 - Protéus announces the launching of "Immuno'line™", a new range of services which is marketed by its PSI (Proteus Services for Industry) division..Immuno'Line™ offers to the pharmaceutical industry new tools to evaluate the risks that a therapeutic protein candidate would induce an immune response and to determine the epitopes associated with such immunogenicity...This technology has been developed by CEA-DSV (French Commission for Atomic Energy – Life Science Division) thanks to the expertise of its department of protein engineering (Institute of Biology and Technologies - IBITECs based in Saclay)... Proteus' Press Release -